<DOC>
	<DOC>NCT01155713</DOC>
	<brief_summary>This study will evaluate the relative bioavailability of 2 oral formulations of TKI258, and the effect of food on the bioavailability of TKI258, in adult patients with advanced solid tumor.</brief_summary>
	<brief_title>Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Patients with an advanced solid tumor which has progressed despite standard therapy, or for which no standard therapy exists World Health Organization (WHO) performance status â‰¤ 2 Patient must meet protocolspecified laboratory values Patients with brain cancer Patients who have concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study Patients who have not recovered from previous anticancer therapies Female patients who are pregnant, breast feeding, or not willing to use an effective method of birth control Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Neoplasms</keyword>
	<keyword>Cancer</keyword>
	<keyword>Tumors</keyword>
	<keyword>Administration, oral</keyword>
	<keyword>Capsules</keyword>
	<keyword>CHIR258, CHIR-258, CHIR 258, TKI258, TKI-258, TKI 258,</keyword>
	<keyword>Bioavailability,</keyword>
	<keyword>Food</keyword>
</DOC>